Caution with the use of dexamethasone in patients with COVID-19 in its initial phases.

Autor: Callejas Rubio JL; Unidad de Enfermedades Autoinmunes Sistémicas, Servicio de Medicina Interna, Hospital Universitario Clínico San Cecilio, Granada, Spain. Electronic address: jlcalleja@telefonica.net., Aomar Millan I; Servicio de Medicina Interna, Hospital Universitario Clínico San Cecilio, Granada, Spain., Moreno-Higueras M; Servicio de Medicina Interna, Hospital Universitario Clínico San Cecilio, Granada, Spain., Martín Ripoll L; Servicio de Neumología, Hospital Universitario Clínico San Cecilio, Granada, Spain., Yuste Osorio E; Servicio de Cuidados Intensivos, Hospital Universitario Clínico San Cecilio, Granada, Spain., Ríos-Fernández R; Unidad de Enfermedades Autoinmunes Sistémicas, Servicio de Medicina Interna, Hospital Universitario Clínico San Cecilio, Granada, Spain.
Jazyk: angličtina
Zdroj: Revista clinica espanola [Rev Clin Esp (Barc)] 2021 Dec; Vol. 221 (10), pp. 592-595. Date of Electronic Publication: 2021 Sep 17.
DOI: 10.1016/j.rceng.2021.02.005
Abstrakt: Introduction: The effect of dexamethasone in the initial phase of infection by SARS-CoV-2 and its influence on COVID-19 is not well defined. We describe clinical-radiological characteristics, the cytokine storm parameters, and the clinical evolution of a series of patients treated with dexamethasone in the disease's initial phase.
Method: A study of 8 patients who received dexamethasone before the development of COVID-19. We evaluate clinical variables, imaging tests, cytokine release parameters, treatment used and patient evolution.
Results: All patients received a 6 mg/day dose with a mean duration of 4.5 days before admission. High resolution computed tomography (HRCT) revealed that most of them presented a severe extension; most patients had a slightly elevated level of cytokine release parameters. Three patients required high-flow oxygen therapy due to respiratory failure; none required orotracheal intubation or died.
Conclusion: Dexamethasone in the early stages of SARS-CoV-2 infection appears to be associated with severe COVID-19.
(Copyright © 2021 Elsevier España, S.L.U. and Sociedad Española de Medicina Interna (SEMI). All rights reserved.)
Databáze: MEDLINE
Externí odkaz: